UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063646
Receipt number R000072834
Scientific Title Effects of consumption of the test food on swelling in healthy Japanese: a randomized, placebo-controlled, double-blind, crossover comparison study
Date of disclosure of the study information 2026/11/16
Last modified on 2026/11/16 12:13:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of consumption of the test food on swelling in healthy Japanese: a randomized, placebo-controlled, double-blind, crossover comparison study

Acronym

Effects of consumption of the test food on swelling in healthy Japanese: a randomized, placebo-controlled, double-blind, crossover comparison study

Scientific Title

Effects of consumption of the test food on swelling in healthy Japanese: a randomized, placebo-controlled, double-blind, crossover comparison study

Scientific Title:Acronym

Effects of consumption of the test food on swelling in healthy Japanese

Region

Japan


Condition

Condition

Healthy Japanese

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify the effects of consumption of the test food on swelling in healthy Japanese.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1. The value of calf circumference in the evening

Key secondary outcomes

1. The values in the morning and the difference between evening and morning (evening minus morning) of calf circumference

2. The measured values of Visual Analogue Scale (VAS) for "I feel swelling face (cheeks or face line)," "I feel swelling around eyes," "I feel swelling calves," "I feel swelling the ankle (such as my socks feeling tight)," "I feel my complexion looks poor," and "I feel dark circles under my eyes".

3. The measured values of body weight, body mass index (BMI), body fat percentage, lean body mass, fat mass (whole body, right leg, left leg, right arm, left arm, trunk), muscle mass (whole body, right leg, left leg, right arm, left arm, trunk), and the changes and percentage changes of them from the measured values in the morning

4. Individuals who experienced adverse events

5. Physical measurements, urinalysis, and peripheral blood test


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Educational,Counseling,Training

Type of intervention

Food

Interventions/Control_1

<Duration>
Two weeks each (two test periods)
<Test product>
Test 1: Capsule containing camellia seeds extract powder
Test 2: Capsule containing dextrin
Prescribed meals: Charcoal grilled silver salmon onigiri (SEVEN-ELEVEN), Tuna mayonnaise onigiri (SEVEN-ELEVEN)
<Administration>
Test 1: Consume one capsule per day with water.
Test 2: Consume one capsule per day with water.
Prescribed meals: Consume each meal at any time between 11:00 and 13:00 on each test day.

*Washout period is two weeks or more.
*If a dose is missed, it should be consumed as soon as remembered. The daily dose should be consumed within the same day and should not be carried over to the following day.
*The intervention sequence is Test 1 to Test 2.
*The contents of the prescribed meals will be reviewed periodically, taking into account factors such as product sales performance.

Interventions/Control_2

<Duration>
Two weeks each (two test periods)
<Test product>
Test 1: Capsule containing dextrin
Test 2: Capsule containing camellia seeds extract powder
Prescribed meals: Charcoal grilled silver salmon onigiri (SEVEN-ELEVEN), Tuna mayonnaise onigiri (SEVEN-ELEVEN)
<Administration>
Test 1: Consume one capsule per day with water.
Test 2: Consume one capsule per day with water.
Prescribed meals: Consume each meal at any time between 11:00 and 13:00 on each test day.

*Washout period is two weeks or more.
*If a dose is missed, it should be consumed as soon as remembered. The daily dose should be consumed within the same day and should not be carried over to the following day.
*The intervention sequence is Test 1 to Test 2.
*The contents of the prescribed meals will be reviewed periodically, taking into account factors such as product sales performance.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Japanese

2. Men or women

3. Adults

4. Healthy individuals

5. Individuals with no abnormalities in kidney function as determined by urinalysis at screening (Scr)

6. Individuals whose BMI is >=18.5 kg/m2 and <30 kg/m2

7. Individuals whose systolic blood pressure is < 130 mmHg and diastolic blood pressure is < 90 mmHg at Scr

Key exclusion criteria

1. Individuals who are receiving treatment for or have a history of malignant tumors, heart failure, or myocardial infarction

2. Individuals who have an implanted pacemaker or implantable cardioverter defibrillator

3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases

4. Individuals who consume Foods for Specified Health Uses or Foods with Functional Claims

5. Individuals who are taking or using medications (including herbal medicines) or supplements

6. Individuals who are allergic to medications or foods related to the test product

7. Individuals who have irregular lifestyles by night work, shift work, or others

8. Individuals who take foods/beverages, medications, or others that may affect swelling

9. Individuals whose menstrual cycle has been < 25 days or > 38 days in the last two menstrual cycles

10. Individuals whose working form is outside work, such as outdoor works or sales calls

11. Individuals who are pregnant, lactating, or planning pregnancy during this study

12. Individuals who have participated in other clinical studies within 28 days before informed consent, or plan to participate in another study during this study

13. Individuals who are deemed unsuitable for participation in this study by the principal investigator

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Tsuyoshi
Middle name
Last name Takara

Organization

Medical Corporation Seishinkai, Takara Clinic

Division name

Director

Zip code

141-0022

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

TEL

03-5793-3623

Email

t-takara@takara-clinic.com


Public contact

Name of contact person

1st name Naoko
Middle name
Last name Suzuki

Organization

ORTHOMEDICO Inc.

Division name

R&D Department

Zip code

112-0002

Address

2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan

TEL

03-3818-0610

Homepage URL


Email

nao@orthomedico.jp


Sponsor or person

Institute

Iwase Cosfa Co.,Ltd.

Institute

Department

Personal name



Funding Source

Organization

Iwase Cosfa Co.,Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethical committee of the Takara Clinic, Medical Corporation Seishinkai

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

Tel

03-5793-3623

Email

IRB@takara-clinic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)


Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2026 Year 10 Month 21 Day

Date of IRB

2026 Year 10 Month 21 Day

Anticipated trial start date

2026 Year 11 Month 16 Day

Last follow-up date

2027 Year 03 Month 08 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2026 Year 11 Month 16 Day

Last modified on

2026 Year 11 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072834